ABSI
ACHAT TOTAL: 12900 titres (~148866 USD)
- Insiders
- Szela Mary T
- Total bought
- $148,866
- Total sold
- —
- Last activity
- 2026-06-30
- Last synced
-
2026-08-04 10:23:03
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-03
ABSI presents a conflicted profile: a genuine Phase I clinical catalyst (ABSI-201 hair loss data) supported by an insider purchase post-surge lends short-term event-driven interest, but the fundamental backdrop is…
The first sentence of the analysis written for ABSI on 2026-08-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | -319.4% | -1277.6% | -731.9% | -925.0% | -832.4% | |
| Ebit Margin | -4103.8% | -2370.7% | -1638.3% | -1816.5% | -1554.5% | |
| Ebitda Margin | -3684.4% | -2075.4% | -1393.5% | -1589.6% | -1415.4% | |
| Operating Profit Margin | -4454.2% | -2401.6% | -2020.2% | -1857.5% | -1573.4% | |
| Pretax Profit Margin | -4111.2% | -2272.5% | -1931.9% | -1833.4% | -2297.3% | |
| Continuous Operations Profit Margin | -4113.7% | -2274.1% | -1933.6% | -1825.4% | -2111.3% | |
| Net Profit Margin | -4113.7% | -2274.1% | -1933.6% | -1825.4% | -2111.3% | |
| Bottom Line Profit Margin | -4113.7% | -2274.1% | -1933.6% | -1825.4% | -2159.0% | |
| Current Ratio | 6.570 | 4.670 | 4.079 | 6.173 | 8.065 | |
| Quick Ratio | 6.570 | 4.670 | 4.079 | 5.677 | 7.755 | |
| Solvency Ratio | -3.853 | -2.602 | -2.348 | -1.972 | -1.569 | |
| Cash Ratio | 0.880 | 1.438 | 2.448 | 1.981 | 7.459 | |
| Price To Earnings Ratio | -4.155 | -2.787 | -3.500 | -1.826 | -7.387 | |
| Price To Earnings Growth Ratio | 0.391 | 0.129 | -0.805 | -0.507 | -0.070 | |
| Forward Price To Earnings Growth Ratio | 0.391 | 0.129 | -0.805 | -0.507 | -0.070 | |
| Price To Earnings Diluted Ratio | -4.155 | -2.787 | -3.500 | -1.826 | -7.387 | |
| Price To Earnings Diluted Growth Ratio | 0.391 | 0.129 | -0.805 | -0.507 | -0.070 | |
| Price To Book Ratio | 2.520 | 1.612 | 2.194 | 0.695 | 2.075 | |
| Price To Sales Ratio | 170.483 | 63.703 | 67.597 | 33.196 | 158.869 | |
| Price To Free Cash Flow Ratio | -5.076 | -3.967 | -5.901 | -1.956 | -7.701 | |
| Price To Operating Cash Flow Ratio | -5.137 | -3.989 | -5.980 | -2.345 | -12.537 | |
| Debt To Assets Ratio | 0.025 | 0.047 | 0.073 | 0.072 | 0.047 | |
| Debt To Equity Ratio | 0.028 | 0.056 | 0.090 | 0.084 | 0.055 | |
| Debt To Capital Ratio | 0.027 | 0.053 | 0.083 | 0.077 | 0.052 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.007 | 0.026 | 0.028 | 0.003 | |
| Financial Leverage Ratio | 1.142 | 1.192 | 1.233 | 1.170 | 1.164 | |
| Working Capital Turnover Ratio | 0.024 | 0.046 | 0.046 | 0.029 | 0.032 | |
| Operating Cash Flow Ratio | -4.082 | -2.527 | -2.187 | -2.687 | -1.790 | |
| Operating Cash Flow Sales Ratio | -33.188 | -15.969 | -11.304 | -14.153 | -12.672 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.012 | 1.006 | 1.013 | 1.199 | 1.628 | |
| Debt Service Coverage Ratio | -95.409 | -28.553 | -18.693 | -23.199 | -10.080 | |
| Interest Coverage Ratio | -596.737 | -192.722 | -114.371 | -109.825 | -21.922 | |
| Short Term Operating Cash Flow Coverage Ratio | -106.443 | -26.492 | -19.839 | -27.610 | -25.249 | |
| Operating Cash Flow Coverage Ratio | -17.526 | -7.165 | -4.070 | -3.539 | -3.028 | |
| Capital Expenditure Coverage Ratio | -83.943 | -179.213 | -75.158 | -5.029 | -1.593 | |
| Dividend Paid And Capex Coverage Ratio | -83.943 | -179.213 | -75.158 | -5.029 | -1.593 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -4.484 | -2.739 | -4.142 | -1.684 | -7.788 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | -319.4% | ▲958.2% | ▲497.9% |
| Ebit Margin | -4103.8% | ▼-1733.0% | ▼-1807.0% |
| Ebitda Margin | -3684.4% | ▼-1609.0% | ▼-1652.7% |
| Operating Profit Margin | -4454.2% | ▼-2052.6% | ▼-1992.8% |
| Pretax Profit Margin | -4111.2% | ▼-1838.7% | ▼-1621.9% |
| Continuous Operations Profit Margin | -4113.7% | ▼-1839.6% | ▼-1662.1% |
| Net Profit Margin | -4113.7% | ▼-1839.6% | ▼-1662.1% |
| Bottom Line Profit Margin | -4113.7% | ▼-1839.6% | ▼-1652.5% |
| Current Ratio | 6.570 | ▲1.900 | ▲0.659 |
| Quick Ratio | 6.570 | ▲1.900 | ▲0.820 |
| Solvency Ratio | -3.853 | ▼-1.250 | ▼-1.384 |
| Cash Ratio | 0.880 | ▼-0.559 | ▼-1.962 |
| Price To Earnings Ratio | -4.155 | ▼-1.367 | ▼-0.224 |
| Price To Earnings Growth Ratio | 0.391 | ▲0.262 | ▲0.563 |
| Forward Price To Earnings Growth Ratio | 0.391 | ▲0.262 | ▲0.563 |
| Price To Earnings Diluted Ratio | -4.155 | ▼-1.367 | ▼-0.224 |
| Price To Earnings Diluted Growth Ratio | 0.391 | ▲0.262 | ▲0.563 |
| Price To Book Ratio | 2.520 | ▲0.907 | ▲0.700 |
| Price To Sales Ratio | 170.483 | ▲106.780 | ▲71.713 |
| Price To Free Cash Flow Ratio | -5.077 | ▼-1.109 | ▼-0.156 |
| Price To Operating Cash Flow Ratio | -5.137 | ▼-1.148 | ▲0.861 |
| Debt To Assets Ratio | 0.025 | ▼-0.023 | ▼-0.028 |
| Debt To Equity Ratio | 0.028 | ▼-0.028 | ▼-0.035 |
| Debt To Capital Ratio | 0.027 | ▼-0.026 | ▼-0.031 |
| Long Term Debt To Capital Ratio | 0.000 | ▼-0.007 | ▼-0.013 |
| Financial Leverage Ratio | 1.142 | ▼-0.051 | ▼-0.039 |
| Working Capital Turnover Ratio | 0.024 | ▼-0.022 | ▼-0.011 |
| Operating Cash Flow Ratio | -4.082 | ▼-1.555 | ▼-1.427 |
| Operating Cash Flow Sales Ratio | -33.188 | ▼-17.219 | ▼-15.730 |
| Free Cash Flow Operating Cash Flow Ratio | 1.012 | ▲0.006 | ▼-0.160 |
| Debt Service Coverage Ratio | -95.409 | ▼-66.855 | ▼-60.222 |
| Interest Coverage Ratio | -596.737 | ▼-404.015 | ▼-389.621 |
| Short Term Operating Cash Flow Coverage Ratio | -106.443 | ▼-79.951 | ▼-65.317 |
| Operating Cash Flow Coverage Ratio | -17.526 | ▼-10.361 | ▼-10.461 |
| Capital Expenditure Coverage Ratio | -83.943 | ▲95.270 | ▼-14.956 |
| Dividend Paid And Capex Coverage Ratio | -83.943 | ▲95.270 | ▼-14.956 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -4.484 | ▼-1.746 | ▼-0.317 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $477.4M | $288.8M | $386.5M | $190.8M | $759.7M | |
| Enterprise value | $462.6M | $257.7M | $330.0M | $153.8M | $527.2M | |
| EV / Sales | 165.22x | 56.84x | 57.72x | 26.76x | 110.24x | |
| EV / Op. cash flow | -4.98x | -3.56x | -5.11x | -1.89x | -8.70x | |
| EV / Free cash flow | -4.92x | -3.54x | -5.04x | -1.58x | -5.34x | |
| EV / EBITDA | -4.48x | -2.74x | -4.14x | -1.68x | -7.79x | |
| Net debt / EBITDA | 0.14x | 0.33x | 0.71x | 0.41x | 3.44x | |
| Current ratio | 6.57x | 4.67x | 4.08x | 6.17x | 8.06x | |
| Income quality | 0.81x | 0.70x | 0.58x | 0.78x | 0.60x | |
| Graham net-net | $1 | $1 | $1 | $1 | $2 | |
| Tax burden | 100.1% | 100.1% | 100.1% | 99.6% | 91.9% | |
| Interest burden | 100.2% | 95.9% | 117.9% | 100.9% | 147.8% | |
| Working capital | $126.8M | $105.2M | $91.0M | $156.6M | $239.2M | |
| Invested capital | $192.1M | $183.2M | $185.1M | $287.6M | $374.2M | |
| Return on assets | -53.3% | -48.3% | -50.9% | -32.7% | -23.7% | |
| Operating ROA | -58.0% | -50.5% | -42.9% | -28.6% | -29.2% | |
| Return on tangible assets | -65.9% | -61.1% | -65.4% | -42.3% | -28.9% | |
| Return on equity | -60.8% | -57.6% | -62.8% | -38.2% | -27.6% | |
| Return on invested capital | -63.6% | -57.5% | -59.8% | -35.7% | -17.3% | |
| Return on capital employed | -64.4% | -58.9% | -61.5% | -36.7% | -19.2% | |
| Earnings yield | -24.1% | -35.7% | -28.6% | -55.0% | -13.3% | |
| Free cash flow yield | -19.7% | -25.2% | -16.9% | -51.1% | -13.0% | |
| Capex / Op. cash flow | -1.2% | -0.6% | -1.3% | -19.9% | -62.8% | |
| Capex / Depreciation | 9.4% | 3.0% | 6.1% | 123.5% | 571.8% | |
| Capex / Sales | 39.5% | 8.9% | 15.0% | 281.5% | 795.6% | |
| SG&A / Sales | 1252.1% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 2907.8% | 1408.4% | 840.6% | 1025.0% | 932.4% | |
| Stock comp / Sales | 654.3% | 429.0% | 199.7% | 218.2% | 221.8% | |
| Intangibles / Total assets | 19.2% | 21.0% | 22.2% | 22.7% | 17.9% | |
| Days sales outstanding | 0d | 0d | 140d | 98d | 109d | |
| Days payables outstanding | 86d | 21d | 12d | 15d | 69d | |
| Operating cycle | 0d | 0d | 140d | 192d | 195d | |
| Cash conversion cycle | -86d | -21d | 128d | 177d | 126d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+65.3%EV / Sales ▲+190.7%EV / EBITDA ▼-63.7%EV / Op. cash flow ▼-1.419Earnings yield ▲+0.116
Profitability
Return on equity ▼-0.032Return on assets ▼-0.050Return on invested capital ▼-0.061Return on capital employed ▼-0.056Operating ROA ▼-0.075Income quality ▲+0.105Tax burden -0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▲+65.047Operating cycle n/aCash conversion cycle ▼-65.047Capex / Sales ▲+0.306R&D / Sales ▲+14.993
Balance-sheet strength
Current ratio ▲+1.900Net debt / EBITDA ▼-0.188Working capital ▲+21633000.000Invested capital ▲+8903000.000Intangibles / Total assets ▼-0.018
Change over 5 years
Valuation
Market cap ▼-37.2%EV / Sales ▲+49.9%EV / EBITDA ▲+42.4%EV / Op. cash flow ▲+3.721Earnings yield ▼-0.108
Profitability
Return on equity ▼-0.332Return on assets ▼-0.296Return on invested capital ▼-0.462Return on capital employed ▼-0.453Operating ROA ▼-0.288Income quality ▲+0.207Tax burden ▲+0.082
Efficiency
Days sales outstanding ▼-108.767Days payables outstanding ▲+17.027Operating cycle ▼-194.831Cash conversion cycle ▼-211.858Capex / Sales ▼-7.561R&D / Sales ▲+19.754
Balance-sheet strength
Current ratio ▼-1.495Net debt / EBITDA ▼-3.293Working capital ▼-112412000.000Invested capital ▼-182103000.000Intangibles / Total assets ▲+0.013
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-07-30 Are Medical Stocks Lagging ABSCI CORP (ABSI) This Year? Here is how Absci Corporation (ABSI) and Acadia Healthcare (ACHC) have performed compared to their sector so far this year.
- 2026-07-24 A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
- 2026-07-14 Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026 VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the second quarter 2026 after market close on Tuesday, August 11, 2026.
- 2026-07-13 Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here''s What You Should Know The average of price targets set by Wall Street analysts indicates a potential upside of 28.3% in ABSCI CORP (ABSI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 2026-07-02 Here''s Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy Does Absci Corporation (ABSI) have what it takes to be a top stock pick for momentum investors? Let''s find out.
- 2026-06-25 ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study Absci stock jumps 36% as interim phase I hair loss study data show ABS-201 is well tolerated and pharmacokinetics support the potential for infrequent dosing.
- 2026-06-25 ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock? ABSCI CORP (ABSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn''t suggest further strength down the road.
- 2026-06-24 Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program Absci Corporation (NASDAQ:ABSI) stock is trading higher on Wednesday after the company reported positive interim Phase 1 results for its investigational anti-prolactin receptor antibody, ABS-201, while also pricing a $100 million underwritten stock offering to support continued development of the program.
- 2026-06-24 Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci
- 2026-06-24 Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts